WASHINGTON, DC (October 4, 2017) — The Association for Accessible Medicines (AAM) announced today that Boehringer Ingelheim Pharmaceuticals, Inc. has joined its Biosimilars Council. Molly Burich, Boehringer Ingelheim’s Associate Director for Public Policy – Biosimilars, Pipeline and Reimbursement, will serve on the Biosimilars Council Board of Directors effective immediately.
“Our members are shaping the U.S. biosimilars market even as it grows and expands,” said Christine Simmon, Executive Director of the Biosimilars Council and Senior Vice President of Policy & Strategic Alliances at AAM. “We are very pleased to welcome Boehringer Ingelheim to the Biosimilars Council and look forward to partnering to make these important medicines accessible to the people who need them most.”
Boehringer Ingelheim is one of the largest producers of biologic medicines in the world. As a pioneer in biologics with more than 35 years of experience, the company has manufactured more than 25 biologic medicines for global markets. This includes monoclonal antibodies in immunology and oncology, interferons and other targeted medicines that are routinely used to treat many patients across a broad range of therapeutic areas. Boehringer Ingelheim further builds on its commitment to immunology and oncology through its efforts develop biosimilars as high-quality, safe and effective treatment options for patients with autoimmune diseases and cancer.
“At Boehringer Ingelheim, we are committed to improving the lives of patients by exploring innovative ways for biosimilars to contribute to the quality and economic sustainability of healthcare,” said Burich. “We are excited to partner with other industry leaders on the Biosimilars Council to make these goals a reality.”
About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation. Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with 145 affiliates and about 50,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine.
Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. To learn more about how we make more health for more people, visit Boehringer Ingelheim’s Corporate Social Responsibility Report. In 2016, Boehringer Ingelheim achieved net sales of about $17.6 billion (15.9 billion euros). R&D expenditure corresponds to 19.6 percent of its net sales.
For more information https://www.boehringer-ingelheim.us or follow @BoehringerUS on Twitter.